Journal of Clinical Oncology
Articles in this Issue
Updated results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
404 Background: PD-1 blockade combined with dual chemotherapy regimens in the first-line setting has exhibited encouraging...
Generalized applicability of da Vinci SP for gastrectomy considering from short-term outcomes, learning curve, and reproducibility.
365 Background: Robot-assisted gastrectomy using da Vinci Xi is increasingly adopted as a minimally invasive approach for...
Genomic and sociodemographic characterization of gastrointestinal cancers in rural patients participating in the Avera Cancer Sequencing and Analytics Protocol (ASAP).
848 Background: Rural populations remain underrepresented in large-scale sequencing initiatives, potentially limiting gene...
Immunohistochemical, genetic, and transcriptomic profiles of jejunoileal adenocarcinoma compared with colorectal adenocarcinoma.
801 Background: Small bowel cancer (SBC) account for less than 1% of all cancers. Jejunal and ileal adenocarcinoma (JIAC)...
Use of PPV of [ <sup>18</sup> F]FAPI-74 PET to identify FAP expression in gastrointestinal cancers: Results from a prospective multicenter phase 2 study.
292 Background: Fibroblast activation protein (FAP) has high expression in cancer associated fibroblasts (CAFs) in the tum...
Comparative efficacy and safety of durvalumab and pembrolizumab combined with chemotherapy in advanced cholangiocarcinoma: A meta-analysis.
576 Background: Cholangiocarcinoma (CAA) is a rare gastrointestinal malignancy by aggressive behavior and poor prognosis....
Cost-effectiveness analysis of systemic therapies for advanced hepatocellular carcinoma.
606 Background: The management of unresectable and metastatic HCC has evolved over the years with the introduction of immu...
Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 alterations (alts): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
127 Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents i...
ACCRU-GI-1810: Trifluridine/tipiracil (FTD-TPI) or paclitaxel (PAC) in combination with ramucirumab (RAM) for patients (pts) with previously treated advanced gastroesophageal adenocarcinoma (GEA)—An investigator-initiated, randomized non-inferiority phase 2 study.
392 Background: PAC+RAM is the standard second-line therapy for advanced GEA. However, PAC-related neuropathy is a major c...
Patterns of care and access to resources in neuroendocrine tumors (NETs): A cross-sectional survey among Mexican oncologists.
630 Background: NETs are uncommon malignancies whose optimal management depends on timely diagnosis, access to specialised...
Pilot study of stomach cancer early detection and prevention with endoscopy (Pilot-SCREEN): Acceptability and feasibility results.
332 Background: Gastric cancer (GC) is a serious disease with high mortality rates, particularly among high-risk (HR) grou...
Trends in hepatocellular carcinoma (HCC) incidence and impact of hepatitis C antiviral therapy: A population-based subgroup analysis.
519 Background: Hepatitis C is one of the most common causes of hepatocellular cancer (HCC) in the United States. Since th...
Disparities in hepatocellular carcinoma outcomes by distance, insurance, and treatment access: A 10-year retrospective study in Nevada.
482 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in the United States, with r...
Adverse events with PD-1 inhibitors in gastric cancer: A real-world comparative study.
423 Background: Programmed death-1 (PD-1) inhibitors such as nivolumab and pembrolizumab have emerged as therapeutic optio...
Levity as a tool for difficult conversations: Healthcare provider experiences with the Butts & Badges colorectal and anal cancer awareness initiative in community health centers.
107 Background: Colorectal & anal cancer conversations remain challenging in healthcare settings. The 'Butts & Bad...
Ultrasensitive structural variant-based ctDNA detection of MRD in colorectal cancer: The CITCCA study.
208 Background: Colorectal cancer (CRC) is the second-leading cause of cancer death globally, with a significant risk of r...
A phase Ib/II study of zanzalintinib (XL092) in second line and beyond for the treatment of advanced hepatocellular carcinoma.
TPS615 Background: Hepatocellular carcinoma (HCC) accounts for 75–85% of primary liver cancers and is responsible for appr...
Molecular profiling and potential therapeutic implications of molecular testing utilizing a large database of hepatocellular carcinoma patients.
594 Background: The incidence of hepatocellular carcinoma (HCC) diagnoses is increasing worldwide with an estimated 1 mill...
Gallbladder and bile duct cancer: A US mortality overview.
588 Background: Biliary tract carcinomas (BTC) affect about 8,000 people annually across the U.S. and present with dismal...
A phase II study of re-introduction of gemcitabine plus cisplatin in combination with durvalumab after durvalumab maintenance therapy in patients with unresectable or recurrent biliary tract cancer (PRIDE study).
TPS609 Background: Biliary tract cancer (BTC) is an aggressive malignancy with limited treatment options and poor prognosi...
Pilot study of cannabidiol (CBD) to prevent neuropathy (CIPN) in colorectal cancer (CRC) chemotherapy (Ctx).
TPS253 Background: Oxaliplatin (Ox) remains a cornerstone of CRC therapy, but its utility is limited by CIPN—a debilitatin...
Number needed to treat/harm (NNT/NNH): A benefit/risk analysis of fruquintinib vs other treatments for metastatic colorectal cancer (mCRC).
126 Background: NNT/NNH analyses can estimate the magnitude of benefit vs harm of therapeutic agents and can inform clinic...
Genomic landscape and clinical outcomes of MDM2 amplifications in biliary tract cancers.
589 Background: Biliary tract cancers (BTCs), including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarc...
LAP-NET1: Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma.
713 Background: Locally advanced Pancreatic Ductal Adenocarcinoma (LAP) accounts for 30–40% of Pancreatic Ductal Adenocarc...
Comparing first-line immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma: A meta-analysis.
578 Background: Liver metastasis is a common manifestation of advanced malignancy. In recent years, novel therapeutic stra...